Literature DB >> 35601940

Human cytomegalovirus and isocitrate dehydrogenase status in glioma: association and prognosis value in Moroccan population.

Coumba Fall1, Mohammed Chaoui El Faiz2, Nawal Hammass3, Hinde El Fatemi3, Khalid Hassouni4, Laila Bouguenouch5, Samira El Fakir6, Bahia Bennani7.   

Abstract

Introduction: Human cytomegalovirus (HCMV) and isocitrate dehydrogenase (IDH) have been separately associated to gliomas. IDH is a molecular marker considered in the histo-molecular classification of gliomas as well as in their management and prognosis. However, even if oncomodulatory properties were attributed to HCMV, its association to gliomas remains a controversy. Most of the studies that investigated this association used the histological classification of gliomas; nevertheless, in 2016, the World Health Organization recommended the introduction of molecular characteristics to refine this classification. The aims of this study were to determine the prevalence of HCMV in glioma patients, the association between HCMV and IDH with gliomas and subsequently their associations with survival of patients in a Moroccan cohort.
Methods: A series of 102 gliomas and 32 controls were analyzed by nested PCR (nPCR) to determine the HCMV status. PCR and sequencing were used to determine the IDH subtypes in tumors samples. IDH mutation and HCMV status were correlated to the characteristics of the tumors using SPSS, whereas the survival curves were obtained by the Kaplan-Meier method and the log rank test.
Results: HCMV shows significant association with gliomas with a detection rate of 30.4% and no case in the control group. The IDH mutation was identified in 40.9-50% of grade II-III gliomas and in 10.9% of grade IV gliomas. A significant association was obtained between survival in patients with glioblastomas and IDH/HCMV status. Glioblastoma patients with HCMV+ and IDHwt had a poor prognostic. Conclusions: HCMV was detected exclusively in tumor cases and was significantly associated with poor prognosis in patients with gliomas and particularly with glioblastomas. The worst overall survival was significantly seen in patients with gliomas HCMV+/IDHwt. So, it will be of interest to consider HCMV and IDH status in gliomas management strategies. GERMS.

Entities:  

Keywords:  Human cytomegalovirus; central nervous system tumors; gliomas; isocitrate dehydrogenase; survival

Year:  2022        PMID: 35601940      PMCID: PMC9113685          DOI: 10.18683/germs.2022.1304

Source DB:  PubMed          Journal:  Germs        ISSN: 2248-2997


  24 in total

1.  Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study.

Authors:  Otto Visser; Eva Ardanaz; Laura Botta; Milena Sant; Andrea Tavilla; Pamela Minicozzi
Journal:  Eur J Cancer       Date:  2015-09-26       Impact factor: 9.162

2.  IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.

Authors:  Chase Robinson; B K Kleinschmidt-DeMasters
Journal:  J Neuropathol Exp Neurol       Date:  2017-02-01       Impact factor: 3.685

3.  Genetic analysis of cytomegalovirus in malignant gliomas.

Authors:  Bornali Bhattacharjee; Nicholas Renzette; Timothy F Kowalik
Journal:  J Virol       Date:  2012-04-11       Impact factor: 5.103

4.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

5.  Human cytomegalovirus infection in Iranian glioma patients correlates with aging and tumor aggressiveness.

Authors:  Faezeh Maleki; Zohreh-Azita Sadigh; Farzin Sadeghi; Ahad Muhammadnejad; Mohammad Farahmand; Mahmoud Parvin; Reza Shirkoohi
Journal:  J Med Virol       Date:  2020-02-04       Impact factor: 2.327

6.  Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

Authors:  Christian Hartmann; Jochen Meyer; Jörg Balss; David Capper; Wolf Mueller; Arne Christians; Jörg Felsberg; Marietta Wolter; Christian Mawrin; Wolfgang Wick; Michael Weller; Christel Herold-Mende; Andreas Unterberg; Judith W M Jeuken; Peter Wesseling; Guido Reifenberger; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2009-06-25       Impact factor: 17.088

7.  Detection of human cytomegalovirus in different histopathological types of glioma in Iraqi patients.

Authors:  Haidar A Shamran; Haider S Kadhim; Aws R Hussain; Abdulameer Kareem; Dennis D Taub; Robert L Price; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh
Journal:  Biomed Res Int       Date:  2015-02-01       Impact factor: 3.411

8.  Human cytomegalovirus seropositivity is associated with decreased survival in glioblastoma patients.

Authors:  Haidn Foster; Keenan Piper; Lisa DePledge; Hsin-Fang Li; James Scanlan; Yoon Jae-Guen; Michael Boeckh; Charles Cobbs
Journal:  Neurooncol Adv       Date:  2019-09-07

9.  Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status.

Authors:  Yusuke Tabei; Keiichi Kobayashi; Kuniaki Saito; Saki Shimizu; Kaori Suzuki; Nobuyoshi Sasaki; Yoshiaki Shiokawa; Motoo Nagane
Journal:  Jpn J Clin Oncol       Date:  2021-01-01       Impact factor: 3.019

Review 10.  The Human Cytomegalovirus, from Oncomodulation to Oncogenesis.

Authors:  Georges Herbein
Journal:  Viruses       Date:  2018-08-03       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.